Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - ravimid hingamisteede obstruktiivsete haiguste, - allergiline asthmaxolair on näidustatud täiskasvanud, noorukid ja lapsed (6 kuni.

Euroopa Liit - eesti - EMA (European Medicines Agency)

recordati ireland ltd - silodosiin - eesnäärme hüperplaasia - uroloogilised ravimid - healoomulise eesnäärme hüperplaasia (bph) sümptomite ravi..

Euroopa Liit - eesti - EMA (European Medicines Agency)

zambon spa - safinamiidmetaansulfonaat - parkinsoni tõbi - parkinsoni tõve ravimid - xadago on näidustatud idiopaatilise parkinsoni tõve (pt) täiskasvanud patsientide ravi ravina levodopa (l-dopa) stabiilsele annusele eraldi või koos muude pd ravimitega kesk-kuni-staadiumis hilisstaadiumis patsientidel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriaas - immunosupressandid - kyntheum on näidustatud mõõduka kuni raske naastulise psoriaasi raviks täiskasvanud patsientidel, kes saavad süsteemset ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriaas - immunosupressandid - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosupressandid - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Eesti - eesti - Ravimiamet

recordati ireland limited - enalapriil+lerkanidipiin - õhukese polümeerikattega tablett - 20mg+20mg 50tk; 20mg+20mg 30tk; 20mg+20mg 98tk; 20mg+20mg 56tk; 20mg+20mg 35tk; 20mg+20mg 14tk; 20mg+20mg 28tk

Eesti - eesti - Ravimiamet

recordati ireland limited - enalapriil+lerkanidipiin - õhukese polümeerikattega tablett - 20mg+10mg 14tk; 20mg+10mg 30tk; 20mg+10mg 50tk; 20mg+10mg 56tk; 20mg+10mg 98tk; 20mg+10mg 7tk; 20mg+10mg 90tk; 20mg+10mg 35tk; 20mg+10mg 100tk

Eesti - eesti - Ravimiamet

recordati ireland limited - metoprolool - toimeainet prolongeeritult vabastav tablett - 50mg 100tk; 50mg 30tk; 50mg 28tk; 50mg 98tk

Eesti - eesti - Ravimiamet

recordati ireland limited - enalapriil+lerkanidipiin - õhukese polümeerikattega tablett - 10mg+10mg 56tk; 10mg+10mg 90tk; 10mg+10mg 42tk; 10mg+10mg 50tk; 10mg+10mg 7tk; 10mg+10mg 30tk; 10mg+10mg 100tk